R Elsby

Summary

Affiliation: AstraZeneca R and D

Publications

  1. ncbi Validation and application of Caco-2 assays for the in vitro evaluation of development candidate drugs as substrates or inhibitors of P-glycoprotein to support regulatory submissions
    R Elsby
    Development Drug Metabolism and Pharmacokinetics and Bioanalysis Charnwood, Loughborough, UK
    Xenobiotica 38:1140-64. 2008
  2. ncbi The utility of in vitro data in making accurate predictions of human P-glycoprotein-mediated drug-drug interactions: a case study for AZD5672
    Robert Elsby
    Clinical Pharmacology and DMPK, AstraZeneca R and D Charnwood, Bakewell Road, Loughborough, Leicestershire, LE11 5RH, UK
    Drug Metab Dispos 39:275-82. 2011
  3. ncbi In vitro risk assessment of AZD9056 perpetrating a transporter-mediated drug-drug interaction with methotrexate
    Robert Elsby
    Clinical Pharmacology and DMPK, AstraZeneca Research and Development Charnwood, Loughborough, Leicestershire, United Kingdom
    Eur J Pharm Sci 43:41-9. 2011
  4. ncbi Validation of membrane vesicle-based breast cancer resistance protein and multidrug resistance protein 2 assays to assess drug transport and the potential for drug-drug interaction to support regulatory submissions
    Robert Elsby
    Clinical Pharmacology and DMPK, AstraZeneca R and D Charnwood, Loughborough, Leicestershire, UK
    Xenobiotica 41:764-83. 2011
  5. ncbi Validation of cell-based OATP1B1 assays to assess drug transport and the potential for drug-drug interaction to support regulatory submissions
    P Sharma
    Clinical Pharmacology and DMPK, AstraZeneca R and D Charnwood, Loughborough LE11 5RH, UK
    Xenobiotica 40:24-37. 2010

Collaborators

Detail Information

Publications5

  1. ncbi Validation and application of Caco-2 assays for the in vitro evaluation of development candidate drugs as substrates or inhibitors of P-glycoprotein to support regulatory submissions
    R Elsby
    Development Drug Metabolism and Pharmacokinetics and Bioanalysis Charnwood, Loughborough, UK
    Xenobiotica 38:1140-64. 2008
    ..They have been successfully applied to development projects resulting in the identification of two candidate drugs as substrates and inhibitors of P-gp, whereas a third was neither a substrate nor an inhibitor of this transporter...
  2. ncbi The utility of in vitro data in making accurate predictions of human P-glycoprotein-mediated drug-drug interactions: a case study for AZD5672
    Robert Elsby
    Clinical Pharmacology and DMPK, AstraZeneca R and D Charnwood, Bakewell Road, Loughborough, Leicestershire, LE11 5RH, UK
    Drug Metab Dispos 39:275-82. 2011
    ..The observed dose-dependent clinically significant interaction was accurately predicted using calculated [I(2)] and in vitro P-gp inhibition data, confirming AZD5672 to be a P-gp inhibitor in vivo...
  3. ncbi In vitro risk assessment of AZD9056 perpetrating a transporter-mediated drug-drug interaction with methotrexate
    Robert Elsby
    Clinical Pharmacology and DMPK, AstraZeneca Research and Development Charnwood, Loughborough, Leicestershire, United Kingdom
    Eur J Pharm Sci 43:41-9. 2011
    ....
  4. ncbi Validation of membrane vesicle-based breast cancer resistance protein and multidrug resistance protein 2 assays to assess drug transport and the potential for drug-drug interaction to support regulatory submissions
    Robert Elsby
    Clinical Pharmacology and DMPK, AstraZeneca R and D Charnwood, Loughborough, Leicestershire, UK
    Xenobiotica 41:764-83. 2011
    ..The approach builds on earlier validations to support drug registration and extends from those cell-based systems to encompass assay formats using membrane vesicles...
  5. ncbi Validation of cell-based OATP1B1 assays to assess drug transport and the potential for drug-drug interaction to support regulatory submissions
    P Sharma
    Clinical Pharmacology and DMPK, AstraZeneca R and D Charnwood, Loughborough LE11 5RH, UK
    Xenobiotica 40:24-37. 2010
    ..These validated OATP1B1 assays were robust, reproducible, and suitable for routine in vitro evaluation of candidate drugs...